Overview

A Study of Nitazoxanide in the Treatment of AIDS-Related Diarrhea

Status:
Completed
Trial end date:
1996-02-01
Target enrollment:
Participant gender:
Summary
To determine the pharmacokinetics profile of single doses of nitazoxanide (NTZ) in patients with AIDS-related cryptosporidial diarrhea. To determine steady state concentrations of NTZ following repeated dosing. To assess the safety and efficacy of 4 dose levels of NTZ in these patients. Cryptosporidial enterocolitis in AIDS patients is frequently chronic and severe, contributing substantially to morbidity, mortality, and health care costs in this population. NTZ exhibits antimicrobial activity that may extend to Cryptosporidial infection.
Phase:
Phase 1
Details
Lead Sponsor:
Unimed Pharmaceuticals
Treatments:
Nitazoxanide